Zimmer Biomet has ended its license agreement with Bactiguard for some orthopedic products, the infection prevention company said Oct. 2.
Zimmer Biomet's reason was because of "the more complex and lengthier path with the US Food and Drug Administration (FDA) than initially expected," Bactiguard said in a news release. The companies have been in partnership for orthopedic products since 2022.
The partnership will remain intact for Zimmer Biomet's trauma product segment, which was signed in 2019.